Humacyte, Inc. (HUMA)
Nasdaq · Healthcare · Biotechnology
$0.50−4.12%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $139M
- 52-week range
- $0.4848 – $2.55
- 52-week change
- −78.95%
- EPS (trailing)
- −$0.51
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $2.0M
- Net income
- −$40.8M
- Operating margin
- −5306.2%
- Diluted EPS
- −$0.26
- Free cash flow
- −$106M
From the company’s annual report on SEC EDGAR.
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Headquarters: Durham, United States · 184 employees · humacyte.com